Hematology

Latest News

While both are anti-CD20 antibodies, obinutuzumab is a glycoengineered type II CD20 antibody, and rituximab is a type I CD20 antibody, meaning a different mode of binding to CD20 antigen. | Image credit: Eleni - stock.adobe.com
Long-Term Data Show Favorable Survival Outcomes With G-Clb in Treatment-Naive CLL

May 1st 2025

Participants in the CLL11 trial and a smaller group of patients followed after study completion showed improved overall survival with obinutuzumab and chlorambucil (G-Clb) compared with chemotherapy plus rituximab or chemotherapy alone for chronic lymphocytic leukemia (CLL).

Researchers analyzed matched cohorts of patients who received either decitabine-cedazuridine with venetoclax or decitabine-cedazuridine alone to determine how the addition of venetoclax impacts outcomes in higher-risk MDS and CMML. |Image credit: syahrir - stock.adobe.com
Adding Venetoclax to Decitabine-Cedazuridine Improves Response in MDS Subgroups

April 25th 2025

Tailored approaches help patients with MM find the regimen that works best for them, which improves quality of life and outcomes | image credit: Dzmitry - stock.adobe.com
Tailored Dosing for MM Matters More Than Drug Count: Ajai Chari, MD

April 25th 2025

The investigators found that people with MPNs and at least one CVRF had an increased risk of both death and arterial or venous thrombosis. | Image credit: Dr_Microbe - stock.adobe.com
Cardiovascular Risk Factors Impact Outcomes in MPNs

April 21st 2025

While pausing therapy did not affect response to vaccination, the investigators noted that participants who paused therapy did have higher rates of self-reported lymphadenopathy. | Image credit: Konstantin Yuganov - stock.adobe.com
Pausing BTK Inhibitors Does Not Strengthen COVID Vaccination in CLL

April 18th 2025

Expanding Horizons: The Present and Future of Bispecific Antibodies Across Oncology

Experts explore the latest bispecific antibody approvals and clinical applications, discuss barriers in community oncology, address management of cytokine release syndrome, and consider how these therapies can expand patient access to care.

AJMC Peer Exchange logo

More News

Mutation in T-Cell ALL Enables Cancer Cells to Survive Chemotherapy
June 27th 2018

Mutation in T-Cell ALL Enables Cancer Cells to Survive Chemotherapy

Laura Joszt, MA
Cancer cells can take advantage of the BCL-2 protein to survive chemotherapy, but a drug that suppresses BCL-2 may have promise in patients with leukemia who produce too much of the protein.
Patients With Myelofibrosis Treated With JAK1/2 Inhibitors at Increased Risk of Lymphomas
June 22nd 2018

Patients With Myelofibrosis Treated With JAK1/2 Inhibitors at Increased Risk of Lymphomas

Laura Joszt, MA
Patients with myelofibrosis who were treated with Janus-kinase (JAK) 1/2 inhibitors have an increased risk for developing B-cell lymphoma. However, researchers believe there is a pre-existing B-cell clone that patients can be tested for before treatment.
Quizartinib Prolongs Overall Survival in Deadly Form of AML Compared With Chemotherapy
June 19th 2018

Quizartinib Prolongs Overall Survival in Deadly Form of AML Compared With Chemotherapy

Laura Joszt, MA
An investigational drug has prolonged survival in patients with a rare and deadly form of acute myeloid leukemia (AML).
Dr Michael Thompson Highlights Novel Therapies Being Used in Hematologic Malignancies
June 16th 2018

Dr Michael Thompson Highlights Novel Therapies Being Used in Hematologic Malignancies

Michael Thompson, MD, PhD, FASCO, Aurora Advanced Healthcare, outlines novel therapies being used in the treatment of hematologic malignancies and identified biomarkers for deciding on a treatment approach.
Gene Editing Could Reduce Toxicity of CAR T Treatment in AML
June 15th 2018

Gene Editing Could Reduce Toxicity of CAR T Treatment in AML

Laura Joszt, MA
A new approach using gene editing technology could allow chimeric antigen receptor (CAR) T cells to target CD33 in patients with acute myeloid leukemia (AML) but prevent the cells from attacking healthy stem cells, too.
Translocated Bacteria Can Lead to a Precursor Condition of Leukemia
June 12th 2018

Translocated Bacteria Can Lead to a Precursor Condition of Leukemia

Laura Joszt, MA
A stem cell mutation that leads to bacterial translocation may help identify patients at risk of developing leukemia.
Once-Weekly Carfilzomib Superior to Twice-Weekly Regimen in Relapsed/Refractory Multiple Myeloma
June 6th 2018

Once-Weekly Carfilzomib Superior to Twice-Weekly Regimen in Relapsed/Refractory Multiple Myeloma

Laura Joszt, MA
The interim analysis of the phase 3 A.R.R.O.W. trial found that once-weekly carfilzomib at 70 mg/m2 had superior progression-free survival and overall response rates compared with twice-weekly carfilzomib at 27 mg/m2.
Experimental Drug Creates Durable Remission in Patients With AML With IDH1 Mutations
June 4th 2018

Experimental Drug Creates Durable Remission in Patients With AML With IDH1 Mutations

Laura Joszt, MA
An experimental drug for patients with acute myeloid leukemia (AML) with mutations in the gene encoding isocitrate dehydrogenase 1 (IDH1) was found to be safe with durable remissions.
Analyzing Worries in Leukemia and Economic Burden in Lymphoma
June 2nd 2018

Analyzing Worries in Leukemia and Economic Burden in Lymphoma

Laura Joszt, MA
Two abstracts presented at the International Society of Pharmacoeconomic and Outcomes Research Annual International Meeting highlighted patient experiences in blood cancers. One highlighted the worries of patients with acute myeloid leukemia, and the other analyzed economic burdens and resource utilization for patients with non-Hodgkin lymphoma.
Studies Highlight the Cost Burden of Diffuse Large B-Cell Lymphoma
May 31st 2018

Studies Highlight the Cost Burden of Diffuse Large B-Cell Lymphoma

Laura Joszt, MA
Two study abstracts presented at the International Society of Pharmacoeconomics and Outcomes Research Annual International Meeting look at the cost burden of diffuse large B-cell lymphoma (DLBCL). One analyzed the lifetime cost of relapsed/refractory DLBCL, including third-line and subsequent treatments, and the other examined how being diagnosed with DBLCL can increase the cost burden of chronic conditions among Medicare beneficiaries.
Analysis Outlines Global Burden of Multiple Myeloma, Access to Effective Treatments
May 26th 2018

Analysis Outlines Global Burden of Multiple Myeloma, Access to Effective Treatments

Laura Joszt, MA
A new study analyzed the burden of multiple myeloma around the world, as well as access to effective treatments. From 1990 to 2016, incident cases and deaths from the disease have grown substantially.
Patients With ALL Taking Inotuzumab Ozogamicin Report Better Quality of Life Compared With Standard Therapy
May 24th 2018

Patients With ALL Taking Inotuzumab Ozogamicin Report Better Quality of Life Compared With Standard Therapy

Laura Joszt, MA
Analysis of patient-reported outcomes found patients with relapsed/refractory B-cell acute lymphoblastic leukemia who were treated with inotuzumab ozogamicin reported better quality of life, functioning, and symptom scores compared with patients receiving standard-of-care chemotherapies.
Site Logo
May 18th 2018

Study Reports Highest Survival Rates for Children, Young Adults With Certain T-Cell Leukemias

Laura Joszt, MA
A phase III randomized trial, with results being presented in June at the American Society of Clinical Oncology Annual Meeting, found the addition of nelarabine to standard chemotherapy regimen in patients with T-cell malignancies can improve disease-free survival rates.
FDA Approves Epoetin Alfa Biosimilar for Anemia
May 15th 2018

FDA Approves Epoetin Alfa Biosimilar for Anemia

Jaime Rosenberg
The FDA has approved Pfizer’s epoetin alfa-epbx (Retacrit), a biosimilar to epoetin alfa (Epogen), marking the first biosimilar approval of 2018 and the first biosimilar erythropoiesis-stimulating agent approved in the United States.
CAR T Therapy Case Study Shows Early Success in Treatment of Acute Myeloid Leukemia
May 9th 2018

CAR T Therapy Case Study Shows Early Success in Treatment of Acute Myeloid Leukemia

Samantha DiGrande
A new case study found that an acute myeloid leukemia patient has remained cancer free for 9 months following treatment with the chimeric antigen receptor (CAR) T-cell treatment, CYAD-01, and a bone marrow transplant.
Daratumumab Approved as Frontline Treatment in Newly Diagnosed Multiple Myeloma
May 8th 2018

Daratumumab Approved as Frontline Treatment in Newly Diagnosed Multiple Myeloma

Laura Joszt, MA
The FDA has approved daratumumab in combination with bortezomib, melphalan, and prednisone to treat patients with newly diagnosed multiple myeloma who are ineligible for autologous stem cell transplant.
This Week in Managed Care: May 4, 2018
May 4th 2018

This Week in Managed Care: May 4, 2018

This week, the top managed care stories included a report that insurance coverage gains are reversing; a deal to lower the cost of Praluent for Express Scripts members; findings that synthetic opioids are playing a bigger role in overdose deaths.
FDA Approves CAR T-Cell Treatment Kymriah for Adult B-Cell Lymphoma
May 2nd 2018

FDA Approves CAR T-Cell Treatment Kymriah for Adult B-Cell Lymphoma

Jaime Rosenberg
Tisagenlecleucel, sold as Kymriah, has gained its second indication following the FDA's approval of the chimeric antigen receptor T-cell therapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma, the most common form of non-Hodgkin lymphoma.
What We're Reading: Kymriah's Second Indication; NIH All of Us Database; Kansas' Medicaid Lifetime Limits
May 2nd 2018

What We're Reading: Kymriah's Second Indication; NIH All of Us Database; Kansas' Medicaid Lifetime Limits

AJMC Staff
The chimeric antigen receptor T-cell therapy tisagenlecleucel has been approved for a second type of blood cancer; the National Institutes of Health has started recruiting individuals for a database that will include data on more than 1 million people; Kansas’ request to impose a 3-year lifetime limit on Medicaid benefits is testing just how open the Trump administration is to allowing states flexibility.
Dr Shannon Maude: The Novelty of CAR T Treatments Requires Patient Education
May 1st 2018

Dr Shannon Maude: The Novelty of CAR T Treatments Requires Patient Education

Chimeric antigen receptor (CAR) T-cell treatments are still new enough that there are still unknown regarding long-term side effects, which is something patients need to understand before they undergo treatment, said Shannon L. Maude, MD, PhD, of The Children's Hospital of Philadelphia.
Researchers Identify New Gene That Predisposes People to ALL
April 30th 2018

Researchers Identify New Gene That Predisposes People to ALL

Laura Joszt, MA
Researchers have identified a new gene that may predispose individuals to develop acute lymphoblastic leukemia (ALL). In addition, variants in the gene can influence patient response to treatment.
Hemophilia: Treatment Landscape, Costs, and Disease Management
April 26th 2018

Hemophilia: Treatment Landscape, Costs, and Disease Management

Jaime Rosenberg
At the Academy of Managed Care Pharmacy’s Managed Care & Specialty Pharmacy Annual Meeting, experts addressed the cost of treating patients with hemophilia and the importance of care coordination to ensure a more holistic approach toward caring for these patients.
New Test Could Make Multiple Myeloma Diagnosis as Easy as Drawing a Blood Sample
April 23rd 2018

New Test Could Make Multiple Myeloma Diagnosis as Easy as Drawing a Blood Sample

Laura Joszt, MA
A new blood test could negate the need for bone biopsies to diagnose a variety of cancers, including multiple myeloma. The test uses a small, low-cost plastic chip that delivers the same diagnostic information of a biopsy through a simple blood draw.
Novel Drug Shows Promise in Acute Myeloid Leukemia by Suppressing Two Proteins
April 19th 2018

Novel Drug Shows Promise in Acute Myeloid Leukemia by Suppressing Two Proteins

Laura Joszt, MA
A novel drug that targets MDMX and MDM2, which inhibit a protein that suppresses tumors when they are overexpressed, has tripled the median survival rate in an animal model of human acute myeloid leukemia, according to new research.
Dr Thomas LeBlanc on the Importance of Shared Decision Making in Cancer Care
April 18th 2018

Dr Thomas LeBlanc on the Importance of Shared Decision Making in Cancer Care

Thomas LeBlanc, MD, of the Duke Cancer Institute, addresses the importance of adding a palliative care specialist to the cancer care team.
Dr Stephen Schuster: Unique CAR T Toxicities Require Provider Education
April 17th 2018

Dr Stephen Schuster: Unique CAR T Toxicities Require Provider Education

Since patients who receive CAR T-cell therapy experience unique adverse events, there will need to be education for providers who care for these patients, explained Stephen Schuster, MD, of the Perelman School of Medicine.
Identification of Genes Involved With MM Development Could Mean More Personalized Treatments
April 16th 2018

Identification of Genes Involved With MM Development Could Mean More Personalized Treatments

Laura Joszt, MA
The identification of 40 genes involved with the development of multiple myeloma could lead to the development of more personalized treatments.
Survivors of Childhood ALL Have Risk of Neurocognitive Issues Even Before Treatment
April 14th 2018

Survivors of Childhood ALL Have Risk of Neurocognitive Issues Even Before Treatment

Laura Joszt, MA
While increased risk of neurocognitive issues, such as long-term problems with attention, is common in survivors of childhood acute lymphoblastic leukemia (ALL), the risk may actually begin before treatment, according to a study published in JAMA Oncology.
Study Revises Molecular Classification of Diffuse Large B-Cell Lymphoma
April 14th 2018

Study Revises Molecular Classification of Diffuse Large B-Cell Lymphoma

Jaime Rosenberg
Researchers have identified genetic subtypes of diffuse large B-cell lymphoma that revise the molecular classification of the disease and could provide insight into why some patients respond to treatment and others don’t.
Pediatric Sickle Cell Disease Drug Gains European Orphan Designation
April 8th 2018

Pediatric Sickle Cell Disease Drug Gains European Orphan Designation

Kelly Davio
Sancilio Pharmaceuticals announced that it has received the European Medicines Agency’s Orphan Designation for its SC411 (which it plans to market as Altemia), a proposed treatment for sickle cell disease in pediatric patients, in the European Union. The FDA granted the proposed drug a similar designation—the Rare Pediatric Disease designation—in 2017.
<1
...
161718192021222324
...
26>

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

© 2025 MJH Life Sciences® and AJMC®.
All rights reserved.

About
Contact
Editorial Boards
Advertise
Do Not Sell My Information
Terms & Conditions
Privacy Policy
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo